Advances in Antibody Design

Annual Review of Biomedical Engineering

Volumn 17, Issue , 2015, Pages 191-216

  Tiller, Kathryn E ^a   Tessier, Peter M ^a  

^a RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

CDR; Complementarity determining region; Fab; IgG; ScFv; VH

Indexed keywords

BINDING ENERGY; BINS; CHEMICAL MODIFICATION; MONOCLONAL ANTIBODIES; SCAFFOLDS;

CDR; COMPLEMENTARITY-DETERMINING REGIONS; FAB; IGG; SCFV; VH;

ANTIBODIES;

ANTIBODY CONJUGATE; BISPECIFIC ANTIBODY; DRUG ANTIBODY; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VASCULOTROPIN;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; BINDING AFFINITY; BINDING SITE; BIOLOGICAL ACTIVITY; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG CONJUGATION; DRUG DESIGN; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; HEPATITIS C VIRUS; HUMAN; MOLECULAR EVOLUTION; MUTAGENESIS; PROCESS OPTIMIZATION; PROTEIN INTERACTION; REVIEW; STATIC ELECTRICITY; ANIMAL; CHEMISTRY; DIRECTED MOLECULAR EVOLUTION; GENETICS; METABOLISM; MOLECULAR MODEL; PROCEDURES; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STABILITY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; DIRECTED MOLECULAR EVOLUTION; HUMANS; IMMUNOCONJUGATES; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN STABILITY;

EID: 84949487027     PISSN: 15239829     EISSN: 15454274     Source Type: Book Series    
DOI: 10.1146/annurev-bioeng-071114-040733     Document Type: Review

References (150)

1. Gitlin D. 1966. Current aspects of the structure, function, and genetics of the immunoglobulins. Annu. Rev. Med. 17:1-22
2. Bradbury AR, Sidhu S, Dubel S, McCafferty J. 2011. Beyond natural antibodies: the power of in vitro display technologies. Nat. Biotechnol. 29:245-54
3. Reichert JM. 2013. Which are the antibodies to watch in 2013? mAbs 5:1-4
4. Lowe D, Dudgeon K, Rouet R, Schofield P, Jermutus L, Christ D. 2011. Aggregation, stability, and formulation of human antibody therapeutics. Adv. Protein Chem. Struct. Biol. 84:41-61
5. Perchiacca JM, Tessier PM. 2012. Engineering aggregation-resistant antibodies. Annu. Rev. Chem. Biomol. Eng. 3:263-86
6. Ratanji KD,Derrick JP,Dearman RJ,Kimber I. 2014. Immunogenicity of therapeutic proteins: influence of aggregation. J. Immunotoxicol. 11:99-109
7. Connolly BD, Petry C, Yadav S, Demeule B, Ciaccio N, et al. 2012. Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter. Biophys. J. 103:69-78
8. Pantazes RJ, Maranas CD. 2010. OptCDR: A general computational method for the design of antibody complementarity determining regions for targeted epitope binding. Protein Eng. Des. Sel. 23:849-58
9. Li T, PantazesRJ, MaranasCD. 2014.OptMAVEn-Anew framework for the de novo design of antibody variable region models targeting specific antigen epitopes. PLOS ONE 9:e105954
10. Moroncini G, Kanu N, Solforosi L, Abalos G, Telling GC, et al. 2004. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc. PNAS 101:10404-9
11. Heppner FL,Musahl C, Arrighi I, Klein MA, Rulicke T, et al. 2001. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294:178-82
12. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, et al. 2001. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412:739-43
13. Solforosi L, Bellon A, Schaller M, Cruite JT, Abalos GC, Williamson RA. 2007. Toward molecular dissection of PrPC-PrPSc interactions. J. Biol. Chem. 282:7465-71
14. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM. 2012. Structure-based design of conformation-And sequence-specific antibodies against amyloid . PNAS 109:84-89
15. Petkova AT, LeapmanRD, GuoZ, YauWM,Mattson MP, Tycko R. 2005. Self-propagating,molecularlevel polymorphism in Alzheimer's-Amyloid fibrils. Science 307:262-65
16. Ladiwala AR, Bhattacharya M, Perchiacca JM, Cao P, Raleigh DP, et al. 2012. Rational design of potent domain antibody inhibitors of amyloid fibril assembly. PNAS 109:19965-70
17. Barbas CF 3rd, Languino LR, Smith JW. 1993. High-Affinity self-reactive human antibodies by design and selection: targeting the integrin ligand binding site. PNAS 90:10003-7
18. Smith JW, Hu D, Satterthwait A, Pinz-Sweeney S, Barbas CF 3rd. 1994. Building synthetic antibodies as adhesive ligands for integrins. J. Biol. Chem. 269:32788-95
19. Kirkham PM, Neri D, Winter G. 1999. Towards the design of an antibody that recognises a given protein epitope. J. Mol. Biol. 285:909-15
20. Koerber JT, Thomsen ND, Hannigan BT, Degrado WF, Wells JA. 2013. Nature-inspired design of motif-specific antibody scaffolds. Nat. Biotechnol. 31:916-21
21. Stoevesandt O, Taussig MJ. 2013. Phospho-specific antibodies by design. Nat. Biotechnol. 31:889-91
22. Lippow SM, Wittrup KD, Tidor B. 2007. Computational design of antibody-Affinity improvement beyond in vivo maturation. Nat. Biotechnol. 25:1171-76
23. Marvin JS, Lowman HB. 2003. Redesigning an antibody fragment for faster association with its antigen. Biochemistry 42:7077-83
24. Clark LA, Boriack-Sjodin PA, Eldredge J, Fitch C, Friedman B, et al. 2006. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci. 15:949-60
25. Tharakaraman K, Robinson LN, Hatas A, Chen YL, Siyue L, et al. 2013. Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency. PNAS 110:E1555-64
26. Kiyoshi M, Caaveiro JM, Miura E, Nagatoishi S, Nakakido M, et al. 2014. Affinity improvement of a therapeutic antibody by structure-based computational design: generation of electrostatic interactions in the transition state stabilizes the antibody-Antigen complex. PLOS ONE 9:e87099
27. Kuroda D, Shirai H, Jacobson MP, Nakamura H. 2012. Computer-Aided antibody design. Protein Eng. Des. Sel. 25:507-21
28. Selzer T, Albeck S, Schreiber G. 2000. Rational design of faster associating and tighter binding protein complexes. Nat. Struct. Biol. 7:537-41
29. Schreiber G, Fersht AR. 1996. Rapid, electrostatically assisted association of proteins. Nat. Struct. Biol. 3:427-31
30. Worn A, Pluckthun A. 2001. Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305:989-1010
31. Honegger A. 2008. Engineering antibodies for stability and efficient folding. In Handbook of Experimental Pharmacology, Vol. 181, ed. Y Chernajovsky, A Nissim, pp. 47-68. Dordrecht, Neth.: Springer
32. Helms LR, Wetzel R. 1995. Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain. Protein Sci. 4:2073-81
33. Yasui H, Ito W, Kurosawa Y. 1994. Effects of substitutions of amino acids on the thermal stability of the Fv fragments of antibodies. FEBS Lett. 353:143-46
34. Zabetakis D, Anderson GP, Bayya N, Goldman ER. 2013. Contributions of the complementarity determining regions to the thermal stability of a single-domain antibody. PLOS ONE 8:e77678
35. Perchiacca JM, Bhattacharya M, Tessier PM. 2011. Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions. Proteins 79:2637-47
36. Ewert S, Honegger A, Pluckthun A. 2004. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 34:184-99
37. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, et al. 2010. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng. Des. Sel. 23:549-57
38. Barthelemy PA, Raab H, Appleton BA, Bond CJ, Wu P, et al. 2008. Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J. Biol. Chem. 283:3639-54
39. Wirtz P, Steipe B. 1999. Intrabody construction and expression III: engineering hyperstableVH domains. Protein Sci. 8:2245-50
40. Tan PH, Sandmaier BM, Stayton PS. 1998. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys. J. 75:1473-82
41. Monsellier E, Bedouelle H. 2006. Improving the stability of an antibody variable fragment by a combination of knowledge-based approaches: validation and mechanisms. J. Mol. Biol. 362:580-93
42. Haidar JN, Yuan QA, Zeng L, Snavely M, Luna X, et al. 2012. A universal combinatorial design of antibody framework to graft distinct CDR sequences: A bioinformatics approach. Proteins 80:896-912
43. Wang N, SmithWF, Miller BR, Aivazian D, Lugovskoy AA, et al. 2009. Conserved amino acid networks involved in antibody variable domain interactions. Proteins 76:99-114
44. Jordan JL, Arndt JW,Hanf K, LiG,Hall J, et al. 2009. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 77:832-41
45. Das R, Baker D. 2008. Macromolecular modeling with Rosetta. Annu. Rev. Biochem. 77:363-82
46. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. 2009. Design of therapeutic proteins with enhanced stability. PNAS 106:11937-42
47. Rothlisberger D, Honegger A, Pluckthun A. 2005. Domain interactions in the Fab fragment: A comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J. Mol. Biol. 347:773-89
48. Wang T, Duan Y. 2011. Probing the stability-limiting regions of an antibody single-chain variable fragment: A molecular dynamics simulation study. Protein Eng. Des. Sel. 24:649-57
49. Kim DY, Kandalaft H, Ding W, Ryan S, van Faassen H, et al. 2012. Disulfide linkage engineering for improving biophysical properties of human VH domains. Protein Eng. Des. Sel. 25:581-89
50. Saerens D, Conrath K, Govaert J,Muyldermans S. 2008. Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J. Mol. Biol. 377:478-88
51. Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, Pastan I. 1994. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng. 7:697-704
52. Young NM, MacKenzie CR, Narang SA, Oomen RP, Baenziger JE. 1995. Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond. FEBS Lett. 377:135-39
53. Wang X, Kumar S, Buck PM, Singh SK. 2013. Impact of deglycosylation and thermal stress on conformational stability of a full length murine IgG2a monoclonal antibody: observations from molecular dynamics simulations. Proteins 81:443-60
54. Ewert S, Honegger A, Pluckthun A. 2003. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. Biochemistry 42:1517-28
55. Lee CC, Perchiacca JM, Tessier PM. 2013. Toward aggregation-resistant antibodies by design. Trends Biotechnol. 31:612-20
56. Perchiacca JM, Lee CC, Tessier PM. 2014. Optimal charged mutations in the complementaritydetermining regions that prevent domain antibody aggregation are dependent on the antibody scaffold. Protein Eng. Des. Sel. 27:29-39
57. Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM. 2012. Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions. Protein Eng. Des. Sel. 25:591-601
58. Wu SJ, Luo J, O'Neil KT, Kang J, Lacy ER, et al. 2010. Structure-based engineering of a monoclonal antibody for improved solubility. Protein Eng. Des. Sel. 23:643-51
59. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, et al. 2012. General strategy for the generation of human antibody variable domains with increased aggregation resistance. PNAS 109:10879-84
60. Jespers L, Schon O, Famm K, Winter G. 2004. Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat. Biotechnol. 22:1161-65
61. Pepinsky RB, Silvian L, Berkowitz SA, Farrington G, Lugovskoy A, et al. 2010. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci. 19:954-66
62. Miklos AE, Kluwe C, Der BS, Pai S, Sircar A, et al. 2012. Structure-based design of supercharged, highly thermoresistant antibodies. Chem. Biol. 19:449-55
63. Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL. 2011. Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. Biotechnol. J. 6:38-44
64. Schaefer JV, Pluckthun A. 2012. Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris andmammalian cell expression. J. Mol. Biol. 417:309-35
65. Buck PM, Kumar S, Singh SK. 2013. Insights into the potential aggregation liabilities of the b12 Fab fragment via elevated temperature molecular dynamics. Protein Eng. Des. Sel. 26:195-205
66. Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. 2012. Developability index: A rapid in silico tool for the screening of antibody aggregation propensity. J. Pharm. Sci. 101:102-15
67. Buck PM, Kumar S, Wang X, Agrawal NJ, Trout BL, Singh SK. 2012. Computational methods to predict therapeutic protein aggregation. Methods Mol. Biol. 899:425-51
68. Tan PH, Chu V, Stray JE, Hamlin DK, Pettit D, et al. 1998. Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility. Immunotechnology 4:107-14
69. Jespers L, Schon O, James LC, Veprintsev D, Winter G. 2004. Crystal structure of HEL4, a soluble, refoldable human VH single domain with a germ-line scaffold. J. Mol. Biol. 337:893-903
70. Arbabi-Ghahroudi M, To R, Gaudette N, Hirama T, Ding W, et al. 2009. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points. Protein Eng. Des. Sel. 22:59-66
71. Ewert S, Cambillau C, Conrath K, Pluckthun A. 2002. Biophysical properties of camelid VHH domains compared to those of human VH3 domains. Biochemistry 41:3628-36
72. Desjarlais JR, Lazar GA. 2011. Modulation of antibody effector function. Exp. Cell Res. 317:1278-85
73. Strohl WR. 2009. Optimization of Fc-mediated effector functions ofmonoclonal antibodies. Curr. Opin. Biotechnol. 20:685-91
74. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, et al. 2001. High resolution mapping of the binding site on human IgG1 for Fc RI, Fc RII, Fc RIII, and FcRn and design of IgG1 variants with improved binding to the Fc R. J. Biol. Chem. 276:6591-604
75. Sondermann P, Huber R, Oosthuizen V, Jacob U. 2000. The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc RIII complex. Nature 406:267-73
76. Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, et al. 2000. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J. Immunol. 164:4178-84
77. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. 2006. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J. Immunol. 177:1129-38
78. TaoMH, Canfield SM, Morrison SL. 1991. The differential ability of human IgG1 and IgG4 to activate complement is determined by theCOOH-terminal sequence of theCH2 domain. J. Exp.Med. 173:1025-28
79. Norderhaug L, Brekke OH, Bremnes B, Sandin R, Aase A, et al. 1991. Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysismore efficiently than IgG3 with normal hinge. Eur. J. Immunol. 21:2379-84
80. Canfield SM, Morrison SL. 1991. The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J. Exp. Med. 173:1483-91
81. Mimoto F, Igawa T, Kuramochi T, Katada H, Kadono S, et al. 2013. Novel asymmetrically engineered antibody Fc variant with superior Fc R binding affinity and specificity compared with afucosylated Fc variant. mAbs 5:229-36
82. Lazar GA, Dang W, Karki S, VafaO, Peng JS, et al. 2006. Engineered antibody Fc variants with enhanced effector function. PNAS 103:4005-10
83. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, et al. 2010. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115:4393-402
84. Liu Z, Gunasekaran K, Wang W, Razinkov V, Sekirov L, et al. 2014. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies. J. Biol. Chem. 289:3571-90
85. Moore GL, Chen H, Karki S, Lazar GA. 2010. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2:181-89
86. Idusogie EE, Wong PY, Presta LG, Gazzano-Santoro H, Totpal K, et al. 2001. Engineered antibodies with increased activity to recruit complement. J. Immunol. 166:2571-75
87. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, et al. 2008. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 68:3863-72
88. Raju TS. 2008. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol. 20:471-78
89. Jefferis R. 2009. Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends Pharmacol. Sci. 30:356-62
90. Simmons LC, Reilly D, Klimowski L, Raju TS, Meng G, et al. 2002. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 263:133-47
91. Jung ST, Reddy ST, Kang TH, Borrok MJ, Sandlie I, et al. 2010. Aglycosylated IgG variants expressed in bacteria that selectively bind Fc RI potentiate tumor cell killing by monocyte-dendritic cells. PNAS 107:604-9
92. Sazinsky SL, Ott RG, Silver NW, Tidor B, Ravetch JV,Wittrup KD. 2008. Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. PNAS 105:20167-72
93. Hodoniczky J, Zheng YZ, James DC. 2005. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol. Prog. 21:1644-52
94. Matsumiya S, Yamaguchi Y, Saito J, Nagano M, Sasakawa H, et al. 2007. Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J. Mol. Biol. 368:767-79
95. Shields RL, Lai J, Keck R, O'Connell LY,Hong K, et al. 2002. Lack of fucose on human IgG1N-linked oligosaccharide improves binding to human Fc RIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277:26733-40
96. Sondermann P, Pincetic A, Maamary J, Lammens K, Ravetch JV. 2013. General mechanism for modulating immunoglobulin effector function. PNAS 110:9868-72
97. Natsume A, Shimizu-Yokoyama Y, Satoh M, Shitara K, Niwa R. 2009. Engineered anti-CD20 antibodies with enhanced complement-Activating capacity mediate potent anti-lymphoma activity. Cancer Sci. 100:2411-18
98. Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, et al. 2013. GA201 (RG7160): A novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin. Cancer Res. 19:1126-38
99. Panowksi S, Bhakta S, Raab H, Polakis P, Junutula JR. 2014. Site-specific antibody drug conjugates for cancer therapy. mAbs 6:34-45
100. Chari RV, MillerML, WiddisonWC. 2014. Antibody-drug conjugates: An emerging concept in cancer therapy. Angew. Chem. Int. Ed. 53:3796-827
101. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. 2009. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 100:1566-72
102. Sievers EL, Senter PD. 2013. Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64:15-29
103. Wang L, Amphlett G, Blattler WA, Lambert JM, Zhang W. 2005. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 14:2436-46
104. Doronina SO, Toki BE, Torgov MY,Mendelsohn BA, Cerveny CG, et al. 2003. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat. Biotechnol. 21:778-84
105. Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, et al. 2005. Reduction-Alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug. Chem. 16:1282-90
106. McDonagh CF, Turcott E,Westendorf L,Webster JB, Alley SC, et al. 2006. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng. Des. Sel. 19:299-307
107. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, et al. 2008. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26:925-32
108. Junutula JR, Bhakta S, Raab H, Ervin KE, Eigenbrot C, et al. 2008. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J. Immunol. Methods 332:41-52
109. Shen BQ, Xu K, Liu L, Raab H, Bhakta S, et al. 2012. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat. Biotechnol. 30:184-89
110. Axup JY, Bajjuri KM, RitlandM,Hutchins BM, Kim CH, et al. 2012. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. PNAS 109:16101-6
111. Hofer T, Skeffington LR, Chapman CM, Rader C. 2009. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry 48:12047-57
112. Boeggeman E, Ramakrishnan B, Pasek M, Manzoni M, Puri A, et al. 2009. Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans ofmonoclonal antibodies usingmutant glycosyltransferases: Application for cell surface antigen detection. Bioconjug. Chem. 20:1228-36
113. Strop P, Liu SH,Dorywalska M, Delaria K, Dushin RG, et al. 2013. Locationmatters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates. Chem. Biol. 20:161-67
114. Jeger S, Zimmermann K, Blanc A, Grunberg J, Honer M, et al. 2010. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew. Chem. Int. Ed. 49:9995-97
115. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, et al. 2004. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin. Cancer Res. 10:7063-70
116. Polson AG, Calemine-Fenaux J,Chan P,ChangW,ChristensenE, et al. 2009. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res. 69:2358-64
117. Nolting B. 2013. Linker technologies for antibody-drug conjugates. Methods Mol. Biol. 1045:71-100
118. Senter PD. 2009. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol. 13:235-44
119. Behrens CR, Liu B. 2014. Methods for site-specific drug conjugation to antibodies. mAbs 6:46-53
120. Klein C, Sustmann C, ThomasM, Stubenrauch K, Croasdale R, et al. 2012. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4:653-63
121. Carter P. 2001. Bispecific human IgG by design. J. Immunol. Methods 248:7-15
122. Holliger P, Winter G. 1993. Engineering bispecific antibodies. Curr. Opin. Biotechnol. 4:446-49
123. Marvin JS, Zhu Z. 2005. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol. Sin. 26:649-58
124. GunasekaranK, Pentony M, ShenM,Garrett L, ForteC, et al. 2010. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecificmolecules andmonovalent IgG. J. Biol. Chem. 285:19637-46
125. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, et al. 2010. SEEDbodies: fusion proteins based on strandexchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23:195-202
126. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, et al. 1998. An efficient route to human bispecific IgG. Nat. Biotechnol. 16:677-81
127. Ridgway JB, Presta LG, Carter P. 1996. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9:617-21
128. LindhoferH,Mocikat R, Steipe B, Thierfelder S. 1995. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155:219-25
129. Strop P, HoWH, Boustany LM, Abdiche YN, Lindquist KC, et al. 2012. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol. 420:204-19
130. Dong J, Sereno A, Aivazian D, Langley E, Miller BR, et al. 2011. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs 3:273-88
131. Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, et al. 2013. Rapid optimization and prototyping for therapeutic antibody-like molecules. mAbs 5:237-54
132. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, et al. 2010. A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel. 23:221-28
133. Coloma MJ, Morrison SL. 1997. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol. 15:159-63
134. Shen J, Vil MD, Jimenez X, Iacolina M, Zhang H, Zhu Z. 2006. Single variable domain-IgG fusion. a novel recombinant approach to Fc domain-containing bispecific antibodies. J. Biol. Chem. 281:10706-14
135. Holliger P, Prospero T, Winter G. 1993. "Diabodies": small bivalent and bispecific antibody fragments. PNAS 90:6444-48
136. Zhu Z, Presta LG, Zapata G, Carter P. 1997. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 6:781-88
137. Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, et al. 2013. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-Antibodies. Nat. Biotechnol. 31:753-58
138. Kostelny SA, Cole MS, Tso JY. 1992. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol. 148:1547-53
139. Atwell S, Ridgway JB, Wells JA, Carter P. 1997. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 270:26-35
140. Schaefer W, Regula JT, Bahner M, Schanzer J, Croasdale R, et al. 2011. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. PNAS 108:11187-92
141. Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, et al. 2014. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol. 32:191-98
142. Wu C, Ying H, Grinnell C, Bryant S, Miller R, et al. 2007. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 25:1290-97
143. Wu C, Ying H, Bose S, Miller R, Medina L, et al. 2009. Molecular construction and optimization of anti-human IL-1/dual variable domain immunoglobulin (DVD-Ig) molecules. mAbs 1:339-47
144. Zuo Z, Jimenez X,Witte L, Zhu Z. 2000. An efficient route to the production of an IgG-like bispecific antibody. Protein Eng. 13:361-67
145. Weitzner BD, Kuroda D, Marze N, Xu J, Gray JJ. 2014. Blind prediction performance of RosettaAntibody 3.0: grafting, relaxation, kinematic loop modeling, and full CDR optimization. Proteins 82:1611-23
146. Shirai H, Ikeda K, Yamashita K, Tsuchiya Y, Sarmiento J, et al. 2014. High-resolution modeling of antibody structures by a combination of bioinformatics, expert knowledge, and molecular simulations. Proteins 82:1624-35
147. Zhu K, Day T. 2013. Ab initio structure prediction of the antibody hypervariable H3 loop. Proteins 81:1081-89
148. Fleishman SJ, Whitehead TA, Ekiert DC, Dreyfus C, Corn JE, et al. 2011. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science 332:816-21
149. Stranges PB,MachiusM,MileyMJ, Tripathy A, Kuhlman B. 2011. Computational design of a symmetric homodimer using-strand assembly. PNAS 108:20562-67
150. Xia Z, Huynh T, Kang SG, Zhou R. 2012. Free-energy simulations reveal that both hydrophobic and polar interactions are important for influenza hemagglutinin antibody binding. Biophys. J. 102:1453-61